journal
MENU ▼
Read by QxMD icon Read
search

PET Clinics

journal
https://www.readbyqxmd.com/read/28267459/prostate-cancer-imaging-in-the-era-of-molecular-medicine
#1
EDITORIAL
Richard P Baum, Cristina Nanni
No abstract text is available yet for this article.
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267458/pet-computed-tomography-for-radiation-therapy-planning-of-prostate-cancer
#2
REVIEW
Kalevi J A Kairemo
This article is a short review of PET tracers, which have been used in clinical routine in single institutions. Preliminary anecdotal research supports the use of PET techniques in therapy planning of prostate cancer. The existing literature is discussed. For external beam radiation therapy, the biological target volume definition can only be based on PET imaging. There are not yet any prospective and randomized trials available; therefore, single-institution experiences cannot yet be recommended as clinical routine...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267457/imaging-of-prostate-cancer-using-urokinase-type-plasminogen-activator-receptor-pet
#3
REVIEW
Dorthe Skovgaard, Morten Persson, Andreas Kjaer
Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using (64)Cu- and (68)Ga-labelled versions of AE105, respectively...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267456/clinical-experience-with-18-f-labeled-small-molecule-inhibitors-of-prostate-specific-membrane-antigen
#4
REVIEW
Steven P Rowe, Michael A Gorin, Roberto A Salas Fragomeni, Alexander Drzezga, Martin G Pomper
Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267455/gallium-68-prostate-specific-membrane-antigen-pet-imaging
#5
REVIEW
Michael S Hofman, Amir Iravani
The role of gallium-68 ((68)Ga) prostate-specific membrane antigen (PSMA) PET imaging is evolving and finding its place in the imaging armamentarium for prostate cancer (PCa). Despite the progress of conventional imaging strategies, significant limitations remain, including identification of small-volume disease and assessment of bone. Clinical studies have demonstrated that (68)Ga-PSMA is a promising tracer for detection of PCa metastases, even in patients with low prostate-specific antigen. To provide an accurate interpretation of (68)Ga-PSMA PET/computed tomography, nuclear medicine specialists and radiologists should be familiar with physiologic (68)Ga-PSMA uptake, common variants, patterns of locoregional and distant spread of PCa, and inherent pitfalls...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267454/from-bench-to-bed-new-gastrin-releasing-peptide-receptor-directed-radioligands-and-their-use-in-prostate-cancer
#6
REVIEW
Theodosia Maina, Berthold A Nock
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate and breast cancer, and are therefore attractive molecular targets for diagnosis and therapy with radiolabeled GRPR-directed peptide probes. The amphibian tetradecapeptide bombesin or the mammalian gastrin-releasing peptide and neuromedin C have been modified with a variety of chelators. As a result, labeling with radiometals attractive for SPECT or PET imaging and for radionuclide therapy has led to the development of peptide radioligands suitable for in vivo targeting of prostate cancer...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267453/imaging-of-prostate-cancer-using-64-cu-labeled-prostate-specific-membrane-antigen-ligand
#7
REVIEW
Aviral Singh, Harshad R Kulkarni, Richard P Baum
Prostate cancer is the most common noncutaneous cancer among men, rendering the diagnosis and staging of significant medical and public interest. One of the most interesting developments in the application of nuclear oncology has been the development of novel diagnostic agents that are able to facilitate targeted therapies using the concept of theranostics. This review summarizes the current and emerging molecular imaging techniques for the investigation of patients with prostate cancer with emphasis on the potential of (64)Cu-PSMA PET/CT in staging, restaging, and the application of theranostics...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267452/clinical-applications-of-molecular-imaging-in-the-management-of-prostate-cancer
#8
REVIEW
Michael A Gorin, Steven P Rowe, Samuel R Denmeade
At the heart of selecting an optimal management strategy for men with prostate cancer is accurately determining a given patient's clinical stage and extent of disease. Molecular imaging with PET using properly selected radiotracers offers the opportunity for improved contrast resolution over conventional imaging and thus increased sensativity for detecting sites of disease. In addition, molecular imaging provides the prospect of obtaining functional or biological information regarding a patient's cancer. To date, several PET radiotracers have been developed for prostate cancer imaging...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267451/imaging-of-prostate-cancer-using-18-f-choline-pet-computed-tomography
#9
REVIEW
Marina Hodolič
(18)F-fluorocholine (FCH) PET/computed tomography (CT) is a valuable imaging modality in prostate cancer disease. Probably, its main role is restaging of patients with biochemical recurrence after radical prostatectomy or external beam radiotherapy. (18)F-FCH PET/CT is strengthening its position in the initial staging, biopsy target definition, radiotherapy planning, and therapy monitoring. Gleason score and prostate-specific antigen value, doubling time, and velocity can influence positivity of (18)F-FCH PET/CT...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267450/imaging-of-prostate-cancer-using-gallium-68-labeled-bombesin
#10
REVIEW
Ida Sonni, Lucia Baratto, Andrei Iagaru
Nuclear medicine can play an important role in evaluating prostate cancer combining anatomical and functional information with hybrid techniques. Various PET radiopharmaceuticals have been used for targeting specific biological markers in prostate cancer. Research is ideally oriented towards the development of radiopharmaceuticals targeting antigens overexpressed in prostate cancer, as opposed to normal prostate tissue. In this regard, gastrin-releasing peptide receptors (GRPR) are excellent candidates. Bombesin analogues targeting the GRPR have been investigated...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267449/imaging-of-prostate-cancer-using-fluciclovine
#11
REVIEW
Bital Savir-Baruch, Lucia Zanoni, David M Schuster
Prostate cancer is the most common cancer and the second leading cause of cancer death in men in the United States. Despite high disease prevalence, diagnosis and surveillance of the disease with conventional imaging are limited typically because of indolent biology. Functional imaging with advanced molecular techniques improves the ability to detect disease. Amino acids are building blocks of proteins, and intracellular transport of amino acids is upregulated in prostate cancer. This review provides a detailed overview of the use of F-18 fluciclovine PET in prostate cancer imaging...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28267448/imaging-of-prostate-cancer-using-11-c-choline-pet-computed-tomography
#12
REVIEW
Paolo Castellucci, Francesco Ceci, Stefano Fanti
This article reviews the role of (11)C-choline-PET/computed tomography (CT) in patients with prostate cancer for diagnosis, staging, and restaging the disease in case of biochemical recurrence after primary treatment. The main application of this imaging procedure is restaging of the disease in case of biochemical recurrence. (11)C-Choline-PET/CT proved its value for metastases-directed salvage therapies and for monitoring therapy response in castration-resistant patients. Prostate-specific antigen and prostate-specific antigen kinetics values confirmed their correlation with (11)C-choline PET/CT sensitivity...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/27863571/precision-medicine-and-pet-computed-tomography-time-has-arrived
#13
EDITORIAL
Rathan M Subramaniam
No abstract text is available yet for this article.
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863570/radionuclide-therapies-in-molecular-imaging-and-precision-medicine
#14
REVIEW
A Tuba Kendi, Valeria M Moncayo, Jonathon A Nye, James R Galt, Raghuveer Halkar, David M Schuster
This article reviews recent advances and applications of radionuclide therapy. Individualized precision medicine, new treatments, and the evolving role of radionuclide therapy are discussed.
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863569/molecular-imaging-and-precision-medicine-in-prostate-cancer
#15
REVIEW
Francesco Ceci, Michelangelo Fiorentino, Paolo Castellucci, Stefano Fanti
The aim of the present review is to discuss about the role of new probes for molecular imaging in the evaluation of prostate cancer (PCa). This review focuses particularly on the role of new promising radiotracers for the molecular imaging with PET/computed tomography in the detection of PCa recurrence. The role of these new imaging techniques to guide lesion-target therapies and the potential application of these molecular probes as theranostics agents is discussed. Finally, the molecular mechanisms underlying resistance to castration in PCa and the maintenance of active androgen receptor are discussed...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863568/molecular-imaging-and-precision-medicine-in-head-and-neck-cancer
#16
REVIEW
Esther Mena, Shwetha Thippsandra, Anusha Yanamadala, Siddaling Redy, Puskar Pattanayak, Rathan M Subramaniam
The concept of using tumor genomic profiling information has revolutionized personalized cancer treatment. Head and neck (HN) cancer management is being influenced by recent discoveries of activating mutations in epidermal growth factor receptor and related targeted therapies with tyrosine kinase inhibitors, targeted therapies for Kristen Rat Sarcoma, and MET proto-oncogenes. Molecular imaging using PET plays an important role in assessing the biologic behavior of HN cancer with the goal of delivering individualized cancer treatment...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863567/advancing-precision-nuclear-medicine-and-molecular-imaging-for-lymphoma
#17
REVIEW
Chadwick L Wright, Joseph J Maly, Jun Zhang, Michael V Knopp
PET with fluorodeoxyglucose F 18 ((18)F FDG-PET) is a meaningful biomarker for the detection, targeted biopsy, and treatment of lymphoma. This article reviews the evolution of (18)F FDG-PET as a putative biomarker for lymphoma and addresses the current capabilities, challenges, and opportunities to enable precision medicine practices for lymphoma. Precision nuclear medicine is driven by new imaging technologies and methodologies to more accurately detect malignant disease. Although quantitative assessment of response is limited, such technologies will enable a more precise metabolic mapping with much higher definition image detail and thus may make it a robust and valid quantitative response assessment methodology...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863566/molecular-imaging-and-precision-medicine-in-lung-cancer
#18
REVIEW
Katherine A Zukotynski, Victor H Gerbaudo
Precision medicine allows tailoring of preventive or therapeutic interventions to avoid the expense and toxicity of futile treatment given to those who will not respond. Lung cancer is a heterogeneous disease functionally and morphologically. PET is a sensitive molecular imaging technique with a major role in the precision medicine algorithm of patients with lung cancer. It contributes to the precision medicine of lung neoplasia by interrogating tumor heterogeneity throughout the body. It provides anatomofunctional insight during diagnosis, staging, and restaging of the disease...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863565/molecular-imaging-and-precision-medicine-in-breast-cancer
#19
REVIEW
Amy V Chudgar, David A Mankoff
Precision medicine, basing treatment approaches on patient traits and specific molecular features of disease processes, has an important role in the management of patients with breast cancer as targeted therapies continue to improve. PET imaging offers noninvasive information that is complementary to traditional tissue biomarkers, including information about tumor burden, tumor metabolism, receptor status, and proliferation. Several PET agents that image breast cancer receptors can visually demonstrate the extent and heterogeneity of receptor-positive disease and help predict which tumors are likely to respond to targeted treatments...
January 2017: PET Clinics
https://www.readbyqxmd.com/read/27863564/designing-and-developing-pet-based-precision-model-in-thyroid-carcinoma-the-potential-avenues-for-a-personalized-clinical-care
#20
REVIEW
Sandip Basu, Rahul Vithalrao Parghane
This communication enumerates the current uses and potential areas where PET could be clinically utilized for developing "precision medicine" type model in thyroid carcinoma. (1) In routine clinics, PET imaging (with fluorodeoxyglucose [FDG]) is utilized to investigate patients of differentiated thyroid carcinoma (DTC) with high thyroglobulin and negative iodine scintigraphy (TENIS) and in medullary carcinoma thyroid (MCT) when the tumor markers (eg, calcitonin and carcino embryonic antigen [CEA]) are raised postoperatively (PET with FDG, (68)Ga-DOTA-NOC/TATE, FDOPA)...
January 2017: PET Clinics
journal
journal
41201
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"